Search results
Results from the WOW.Com Content Network
Patients who require the use of antiplatelet drugs are: stroke with or without atrial fibrillation, any heart surgery (especially prosthetic replacement heart valve), Coronary Heart Disease such as stable angina, unstable angina and heart attack, patients with coronary stent, Peripheral Vascular Disease/Peripheral Arterial Disease and apical ...
After placement of a stent or scaffold, the patient needs to take two antiplatelet medications (aspirin and one of a few other options) for several months to help prevent blood clots. The length of time a patient needs to be on dual antiplatelet therapy is individualized based risks of ischemic events and bleeding risk. [29]
Before-and-after cross sections of the artery show the results of the stent placement. Arterial Stenting 3D Medical Animation. Cardiac stenting is achieved by PCI procedures in two distinct medical situations, when a patient has clearly suffered a heart attack and therefore PCI/stenting is being used in an emergency setting, termed 'primary PCI'.
To prevent blood clots from forming after putting in the stent, most doctors recommend taking a combination of an antiplatelet medication and aspirin for about a year.
Antiplatelet agents and dual antiplatelet therapy. These drugs, which include aspirin, prevent blood clotting in patients with various types of heart disease. ARBs and ARNIs.
Dual antiplatelet therapy (DAPT) is recommended for 1 month following bare metal stent placement, for 3 months following a second generation drug-eluting stent placement, and for 6–12 months following a first generation drug-eluting stent placement. [1]
Clopidogrel, sold under the brand name Plavix among others, is an antiplatelet medication used to reduce the risk of heart disease and stroke in those at high risk. [10] It is also used together with aspirin in heart attacks and following the placement of a coronary artery stent (dual antiplatelet therapy). [10] It is taken by mouth. [10]
[1] [2] As a result, dual therapy stents were developed to reduce the long-term need for dual-antiplatelet therapy. [3] The COMBO stent is the first and only dual therapy stent that addresses the challenges of vessel healing in drug-eluting stents. [4] This stent is an anti-CD34 antibody-coated and sirolimus-eluting bioresorbable stent. [2]